검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AZD2811 |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Small-Cell Lung Cancer |
Overview Indication | Small-Cell Lung Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted agents, including kinase inhibitors targeting cell cycle and oncogenic signal transduction pathway |
MoA Biomarker | biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cance |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.. Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis. AZD2811 is an AURKB inhibitor that demonstrated tolerability during a Phase I dose-escalation study in patients with advanced solid tumours, including small-cell lung c… |
Clinical Primary efficacy | ORR 59.1% |
Clinical ORR | 59.1% |
Clinical PFS | NA |
Clinical OS | 9.99 |
Clinical Result source | ClinicalTrials.gov NCT04745689 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AZD2811 |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Small-Cell Lung Cancer |
Overview Indication | Small-Cell Lung Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targeted agents, including kinase inhibitors targeting cell cycle and oncogenic signal transduction pathway |
MoA Biomarker | biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cance |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancer.. Aurora kinase B (AURKB) is overexpressed in lung cancer and is associated with poor prognosis. AZD2811 is an AURKB inhibitor that demonstrated tolerability during a Phase I dose-escalation study in patients with advanced solid tumours, including small-cell lung c… |
Clinical Primary efficacy | ORR 59.1% |
Clinical ORR | 59.1% |
Clinical PFS | NA |
Clinical OS | 9.99 |
Clinical Result source | ClinicalTrials.gov NCT04745689 |
Clinical Data Tier / Score | A · 47 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교